Craig Thomas Morgan Chepke MD DFAPA (He/Him)
Psychopharmacology, Integrative Psychiatry
Private Practice Psychiatry at Excel Psychiatric Associates
Join to view full profile
10225 Hickorywood Hill AveSuite BHuntersville, NC 28078
Phone+1 704-457-9292
Fax+1 704-274-5783
Dr. Chepke is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalResidency, Psychiatry, 2005 - 2009
New York University School of MedicineClass of 2005
Certifications & Licensure
NC State Medical License 2005 - 2027
SC State Medical License 2021 - 2027
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Distinguished Fellow of the American Psychiatric Association American Psychiatric Association
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2010-2013
Publications & Presentations
PubMed
- Understanding the relationship between aripiprazole levels in the blood and recurrence of mood episodes in people diagnosed with bipolar I disorder treated with a once...Karimah S Bell Lynum, Murat Yildirim, Craig Chepke, Julie Passarell, Matthew Harlin
Expert Review of Clinical Pharmacology. 2026-07-01 - Exposure-Response Analysis for Aripiprazole Once-Monthly in Patients Diagnosed With Bipolar I Disorder.Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S Bell Lynum, Frank Larsen
Clinical Pharmacology in Drug Development. 2025-11-01 - Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia.Craig Chepke, Peter J Weiden, Leslie Citrome
Expert Opinion on Drug Metabolism & Toxicology. 2025-09-01
Press Mentions
FDA Expands Uzedy Indication to Bipolar I DisorderOctober 13th, 2025- FDA Approves Expanded Indication for UZEDY® (Risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I DisorderOctober 10th, 2025
- Teva to Present Latest Research from Neurology Portfolio at the 2022 American Psychiatric Association Annual MeetingMay 17th, 2022
Professional Memberships
- Distinguished Fellow
External Links
- Dr. Chepke's Practicehttp://www.excelpsychiatric.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
